MAPT and Alzheimer disease: The International Working Group (IWG)-2 criteria and the National Institute on Aging-Alzheimer’s Association (NIA-AA) framework (Dubois et al., 2014; Jack et al., 2018) propose cerebrospinal fluid (CSF)-Aβ and CSF-tau as diagnostic biomarkers for AD.